Breaking News
Investing Pro 0
Black Friday SALE: Up to 54% OFF InvestingPro+ CLAIM OFFER
Close

Rigel Pharmaceuticals Inc (RIGL)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Rigel's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.751 -0.008    -1.07%
25/11 - Closed. Currency in USD ( Disclaimer )
After Hours
0.750
-0.001
-0.146%
16:43:22 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 690,856
  • Bid/Ask: 0.730 / 0.760
  • Day's Range: 0.720 - 0.773
Rigel 0.751 -0.008 -1.07%

Rigel Pharmaceuticals Inc Company Profile

 
Get an in-depth profile of Rigel Pharmaceuticals Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology
SectorHealthcare
Employees

165

Equity Type

ORD

Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.

Contact Information

Phone 650 624 1100
Fax 650 624 1101

Top Executives

Name Age Since Title
Raul R. Rodriguez 60 2002 President, CEO & Director
Walter H. Moos 66 1997 Independent Director
Gary A. Lyons 71 2005 Independent Director
Gregory Anthony Lapointe 63 2017 Independent Director
Brian L. Kotzin 73 2017 Independent Director
Alison L. Hannah 61 2021 Independent Director
Kamil Ali-Jackson 63 2021 Independent Director
Jane Wasman 66 2019 Independent Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

RIGL Comments

Write your thoughts about Rigel Pharmaceuticals Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Raul AlKhuwaitem
Raul AlKhuwaitem Aug 13, 2021 7:57AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
#SOS and #EBON, be ready to fly.. #Bitcoin and #Crypto going too high..Lets reach February hights..
Avise Analytics
Avise Aug 09, 2021 8:50AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
https://www.reddit.com/r/MicrocapStocksRun/comments/p105qc/4_biotech_stocks_for_your_investment_watchlist/?utm_source=share&utm_medium=web2x&context=3
DPP TCR
DPP TCR Jun 21, 2021 10:04AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Its started the upward movement
Ziyad Ghanim
Ziyad Ghanim Mar 12, 2021 9:11AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
https://www.smarteranalyst.com/new-blurbs/rigel-rigl-gets-a-buy-rating-from-h-c-wainwright-7/?mod=mw_quote_news
Ziyad Ghanim
Ziyad Ghanim Mar 10, 2021 1:00PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
https://patents.justia.com/assignee/rigel-pharmaceuticals-inc
Eugenio Basilici
Eugenio Basilici Feb 25, 2021 1:19PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
🔴 Rigel Pharmaceuticals (NASDAQ:RIGL) had its price target raised by research analysts at HC Wainwright from $8.00 to $11.00 in a note issued to investors on Thursday. The brokerage presently has a "buy" rating on the biotechnology company's stock. HC Wainwright's price objective points to a potential upside of 156.41% from the stock's previous close.
Daimon van Buren
Daimon van Buren Feb 18, 2021 7:43AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Boom!
gurhan binay
gurhan binay Dec 16, 2020 10:44AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Buy buy
Davide Nuvoli
Davide Nuvoli Aug 08, 2020 2:10PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Sunesis, buy
gurhan binay
gurhan binay Aug 04, 2020 12:00PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
It will take off after aug 11
Alex Hunter
Alex Hunter Aug 04, 2020 12:00PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
May I ask why?
Steve Buchanan
Steve Buchanan Aug 04, 2020 12:00PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
What is 8/11?
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email